The incidence of central nervous system cancer in the US remains largely unchanged from 1990 to 2021, while disability ...

In just the past 8 years since we launched this report, the 5-year survival rate has gone from 18% to nearly 30%,” said Harold Wimmer, President and CEO of the American Lung Association. In the US, ...

This “evolutionary” trial will use tumor biopsies, blood samples, high-resolution imaging, and medical records to monitor ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...